FH535 Inhibited Migration and Growth of Breast Cancer Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Iida, Joji ^a   Dorchak, Jesse ^a   Lehman, John R ^a   Clancy, Rebecca ^a   Luo, Chunqing ^a   Chen, Yaqin ^a   Somiari, Stella ^a   Ellsworth, Rachel E ^a   Hu, Hai ^a   Mural, Richard J ^a   Shriver, Craig D ^b  

^a WINDBER RESEARCH INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; COLLAGEN TYPE 1; FH 535; FOCAL ADHESION KINASE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN CSPG4; PROTEIN NEDD9; PROTEIN TYROSINE KINASE; PROTEOCHONDROITIN SULFATE; SYNAPTOPHYSIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; MITOSIS INHIBITION; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHONDROITIN SULFATE PROTEOGLYCANS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHOPROTEINS; SULFONAMIDES; WNT PROTEINS;

EID: 84866300464     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044418     Document Type: Article

References (54)

1. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE, (2009) WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 11: R32.
2. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG, (2008) Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 14: 4038-4044.
3. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116-4124.
4. Lacroix-Triki M, Geyer FC, Lambros MB, Savage K, Ellis IO, et al. (2010) beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol 23: 1438-1448.
5. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
6. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, et al. (2011) beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
7. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI,et al. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920.
8. Handeli S, Simon JA, (2008) A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther 7: 521-529.
9. Vaid M, Prasad R, Sun Q, Katiyar SK, (2011) Silymarin Targets beta-Catenin Signaling in Blocking Migration/Invasion of Human Melanoma Cells. PLoS One 6: e23000.
10. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, et al. (2001) Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 276: 18786-18794.
11. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, et al. (2004) Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 122: 167-176.
12. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, et al. (1999) Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1: 507-513.
13. Keely PJ, Fong AM, Zutter MM, Santoro SA, (1995) Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci 108 (Pt 2): 595-607.
14. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
15. Carter WG, Wayner EA, Bouchard TS, Kaur P, (1990) The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol 110: 1387-1404.
16. Languino LR, Gehlsen KR, Wayner E, Carter WG, Engvall E, et al. (1989) Endothelial cells use alpha 2 beta 1 integrin as a laminin receptor. J Cell Biol 109: 2455-2462.
17. MacDonald BT, Tamai K, He X, (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
18. Knutson JR, Iida J, Fields GB, McCarthy JB, (1996) CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell 7: 383-396.
19. Bissell MJ, (1999) Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol 155: 675-679.
20. Bissell MJ, Labarge MA, (2005) Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7: 17-23.
21. Bissell MJ, Radisky D, (2001) Putting tumours in context. Nat Rev Cancer 1: 46-54.
22. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, et al. (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6: 11.
23. Wozniak MA, Desai R, Solski PA, Der CJ, Keely PJ, (2003) ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J Cell Biol 163: 583-595.
24. Singh M, Cowell L, Seo S, O'Neill G, Golemis E, (2007) Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys 48: 54-72.
25. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P, (2010) Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10: 858-870.
26. Liu CC, Prior J, Piwnica-Worms D, Bu G, (2010) LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A 107: 5136-5141.
27. Bravo-Cordero JJ, Marrero-Diaz R, Megias D, Genis L, Garcia-Grande A, et al. (2007) MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J 26: 1499-1510.
28. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE, (2009) Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116: 79-90.
29. Paquette B, Therriault H, Desmarais G, Wagner R, Royer R, et al. (2011) Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor. Br J Cancer 105: 534-541.
30. Poincloux R, Collin O, Lizarraga F, Romao M, Debray M, et al. (2011) Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc Natl Acad Sci U S A 108: 1943-1948.
31. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, et al. (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66: 1526-1535.
32. Kenny PA, Lee GY, Bissell MJ, (2007) Targeting the tumor microenvironment. Front Biosci 12: 3468-3474.
33. Provenzano PP, Eliceiri KW, Keely PJ, (2009) Shining new light on 3D cell motility and the metastatic process. Trends Cell Biol 19: 638-648.
34. King TD, Suto MJ, Li Y (2011) The Wnt/beta-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem.
35. Lim SK, Orhant-Prioux M, Toy W, Tan KY, Lim YP, (2011) Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor {alpha} function in breast cancer via the Wnt pathway. Faseb J 25: 3004-3018.
36. Chang JX, Gao F, Zhao GQ, Zhang GJ (2012) Expression and clinical significance of NEDD9 in lung tissues. Med Oncol.
37. Kong C, Wang C, Wang L, Ma M, Niu C, et al. (2011) NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One 6: e22666.
38. Li Y, Bavarva JH, Wang Z, Guo J, Qian C, et al. (2011) HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 30: 2633-2643.
39. Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, et al. (2009) NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res 69: 7198-7206.
40. Iida J, Meijne AM, Knutson JR, Furcht LT, McCarthy JB, (1996) Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 7: 155-162.
41. Iozzo RV, Sanderson RD, (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15: 1013-1031.
42. Campoli M, Ferrone S, Wang X, (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109: 73-121.
43. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, et al. (2011) CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res 24: 1148-1157.
44. Wang X, Wang Y, Yu L, Sakakura K, Visus C, et al. (2010) CSPG4 in cancer: multiple roles. Curr Mol Med 10: 419-429.
45. Iida J, Meijne AM, Oegema TR Jr, Yednock TA, Kovach NL, et al. (1998) A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. J Biol Chem 273: 5955-5962.
46. Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, et al. (1995) Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res 55: 2177-2185.
47. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, et al. (2007) Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 403: 553-563.
48. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, et al. (2009) Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 69: 7538-7547.
49. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, et al. (2004) Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 165: 881-891.
50. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, et al. (2011) Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res 13: R58.
51. Wang X, Osada T, Wang Y, Yu L, Sakakura K, et al. (2010) CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 102: 1496-1512.
52. Legg J, Jensen UB, Broad S, Leigh I, Watt FM, (2003) Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis. Development 130: 6049-6063.
53. Svendsen A, Verhoeff JJ, Immervoll H, Brogger JC, Kmiecik J, et al. (2011) Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 122: 495-510.
54. Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkotter E, et al. (2011) beta-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis 32: 434-442.